Literature DB >> 9433492

Proteases and protease inhibitors in tumor progression.

Y A DeClerck1, S Imren, A M Montgomery, B M Mueller, R A Reisfeld, W E Laug.   

Abstract

Our understanding of the role of matrix degrading proteases in cancer has dramatically expanded over the last two decades. From correlative observations linking proteases to cancer progression, we have accumulated evidence supporting a causal role for proteases in various steps of tumor progression and have become increasingly aware of the complex interactions that exist among proteases. Specific natural inhibitors of these proteases have also been identified and their role as potent cytostatic agents in cancer has been suggested. In this article some of the concepts on the role of proteases in cancer are discussed and examples of cooperation between matrix metalloproteinases and the plasmin/plasminogen activators system are presented. The role of protease inhibitors such as tissue inhibitor of metalloproteinases-2 (TIMP-2) and plasminogen activator inhibitor-2 (PAI-2) as inhibitors of tumor growth, invasion and metastasis is discussed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9433492     DOI: 10.1007/978-1-4615-5391-5_9

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  22 in total

1.  Activity-based protein profiling: the serine hydrolases.

Authors:  Y Liu; M P Patricelli; B F Cravatt
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

2.  Cellular activation of the self-quenched fluorescent reporter probe in tumor microenvironment.

Authors:  Alexei A Bogdanov; Charles P Lin; Maria Simonova; Lars Matuszewski; Ralph Weissleder
Journal:  Neoplasia       Date:  2002 May-Jun       Impact factor: 5.715

3.  A proteinase inhibitor decreases tumor growth in a laparoscopic rat model.

Authors:  M Pross; H Lippert; R Mantke; S Krüger; T Günther; F Marusch; W Halangk; H U Schulz
Journal:  Surg Endosc       Date:  2001-05-02       Impact factor: 4.584

Review 4.  In situ hybridization in the pathology laboratory: general principles, automation, and emerging research applications for tissue-based studies of gene expression.

Authors:  David G Hicks; Gabe Longoria; James Pettay; Tom Grogan; Shannon Tarr; Raymond Tubbs
Journal:  J Mol Histol       Date:  2004-08       Impact factor: 2.611

5.  Induction of the plasminogen activator inhibitor-2 in cells expressing the ZNF198/FGFR1 fusion kinase that is involved in atypical myeloproliferative disease.

Authors:  Chitta S Kasyapa; Padmaja Kunapuli; Lesleyann Hawthorn; John K Cowell
Journal:  Blood       Date:  2006-01-12       Impact factor: 22.113

6.  Neuroserpin is expressed in the pituitary and adrenal glands and induces the extension of neurite-like processes in AtT-20 cells.

Authors:  R M Hill; P K Parmar; L C Coates; E Mezey; J F Pearson; N P Birch
Journal:  Biochem J       Date:  2000-02-01       Impact factor: 3.857

7.  (4-aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase.

Authors:  S Sperl; U Jacob; N Arroyo de Prada; J Stürzebecher; O G Wilhelm; W Bode; V Magdolen; R Huber; L Moroder
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

8.  Cystatin C deficiency in human atherosclerosis and aortic aneurysms.

Authors:  G P Shi; G K Sukhova; A Grubb; A Ducharme; L H Rhode; R T Lee; P M Ridker; P Libby; H A Chapman
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

9.  Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness.

Authors:  Nadim Jessani; Yongsheng Liu; Mark Humphrey; Benjamin F Cravatt
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-29       Impact factor: 11.205

10.  Increased levels of soluble CD226 in sera accompanied by decreased membrane CD226 expression on peripheral blood mononuclear cells from cancer patients.

Authors:  Zhuwei Xu; Tao Zhang; Ran Zhuang; Yun Zhang; Wei Jia; Chaojun Song; Kun Yang; Angang Yang; Boquan Jin
Journal:  BMC Immunol       Date:  2009-06-02       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.